LUCCHINI sets itself apart as a pioneer in the field of skincare, offering a holistic approach to skin transformation
Hims & Hers said its oral semaglutide "empowers providers to tailor treatment plans specifically for those who prefer to avoid needles or need smaller doses to help to balance side-effects." It added that its compounding operations "adhere to all federal and state standards for compounding, and all active pharmaceutical ingredientsin compounded treatments are sourced exclusively from FDA-registered facilities." In its statement, Novo Nordisk said the American Diabetes Association's Obesity Association recently published new standards of care, which "discourage the use of compounded GLP-1s due to safety, quality, and effectiveness concerns." Meanwhile, FDA Commissioner Marty Makary delivered some encouraging news to Novo Nordisk, after pledging "swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products."

Scientific references TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial (NEJM, 2023) Retatrutide for people with type 2 diabetes a Phase 2 trial (The Lancet, 2023) LY3437943 (retatrutide), a triple GIP/GLP-1/glucagon agonist Phase 1b trial MHRA: avoid illegal online weight-loss medicines MHRA Drug Safety Update: GLP-1 / GIP agonists pancreatitis warnings NICE TA875: Semaglutide for overweight and obesity NICE TA1026: Tirzepatide for overweight and obesity Incretin-based drugs and gallbladder / biliary disease (The Lancet) Final word for UK research customers A retatrutide 40mg pen is a pre-filled, ready-to-use research peptide with 40mg in the tank roughly 240 clicks, enough for many small doses or a handful of big ones
Transcript Joey Wahler (Host): There are a hot topic right now, so were discussing GLP-1 medications
Taking a relaxing shower first to soften the skin and calm the nerves